A platform-technology company that provides devices, diagnostics, infection control and imaging for specialists treating a wide range of gastrointestinal diseases.
EndoChoice announced the close of a $57 million financing. Proceeds will go toward continued expansion of sales and marketing efforts of the Fuse Full Spectrum Endoscopy platform.
EndoChoice has been named as one of “Atlanta’s Best and Brightest Companies to Work For™”, a designation that hundreds of companies pursue. EndoChoice was identified as a company that delivers exceptional human resource practices as measured by the National Association for Business Resources.
New Study Published in The Lancet Oncology Shows EndoChoice Fuse System Detects Significantly More Pre-Cancerous Polyps
Fuse™ Colonoscopy dramatically outperforms standard forward-viewing colonoscopes.
Mr. Scott Davis, the Chairman and CEO of UPS (NYSE: UPS) and Mr. Scott Huennekens, President and CEO of Volcano Corporation (NASDAQ: VOLC) have joined the board as EndoChoice looks to more than double its revenue in 2014.
New Study Shows Full Spectrum Endoscopy Procedure Reduces The ‘Miss Rate’ of Adenomas During Colonoscopy
EndoChoice’s Fuse system receives FDA 510(k) Clearance.